// Mechanism
Investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied for its effects on energy balance and metabolic regulation in published Phase 2 clinical trials.
// Pen Configuration (30mg)
Reconstitute with 3ml bacteriostatic water
Final concentration: 10mg/ml
10 units on dial = 1mg
One pen covers ~9 weeks of escalation
// PUBLISHED ESCALATION PROTOCOL (Phase 2 Reference)
| Phase | Duration | Weekly Dose | Pen Dial | Units (Insulin Syringe) |
|---|
| Initiation | Weeks 1–4 | 2mg | 20 units | 20u |
| Escalation 1 | Weeks 5–8 | 4mg | 40 units | 40u |
| Escalation 2 | Weeks 9–12 | 8mg | 80 units | 80u |
| Maintenance | Ongoing | Up to 12mg | 120 units | 120u |
// Pen Duration (30mg / 10mg/ml)
At 4mg/week: ~7.5 weeks
At 8mg/week: ~3.75 weeks
Full escalation: ~9 weeks
At 12mg maintenance: ~2.5 weeks
// Syringe Reading (1ml / 100u insulin)
1 small line = 2 units = 0.2mg
1 numbered line = 10 units = 1mg
⚠ Always count units, not lines. On a 1ml syringe each small line = 2 units.
⚗
Use the Peptide Calculator to compute your exact reconstitution volumes and draw amounts for any dose and vial configuration.
Dosing data referenced from: Jastreboff AM, et al. (2023) "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine 389:514–526. This information is for research reference only and must not be interpreted as prescribing guidance.